Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by Laine1on May 25, 2010 12:04pm
621 Views
Post# 17128840

RE: rjc - trial error or statistical anomoley

RE: rjc - trial error or statistical anomoley
I agree things do not make sense - for many reasons. As you stated, if the results were erroneous, then it could be a computation error, an interpretation error or a scoring error (at either the beginning or the end of the 90 day period.) It is hard for me to say because it would take a serious error to come out with a placebo effect of that magnitude.
We do not normally see this degree of recovery from stroke with no treatment. The reason an improvement in the NIHSS score of 4 was chosen is for that reason - a score of 4 is statistically meaningful. The relevance of the improvement score of 4 points is based on the previous science which has supported the licensing of marketed drugs. 
If it was typical for stroke patients to spontaneously recover to this degree without any medical intervention, there would be no need for treatment drugs
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse